| Saphnelo (anifrolumab-fnia) / AstraZeneca |
2022-000609-28: Efficacy and safety of anifrolumab treatment for 24 weeks in patients with primary Sjögren’s syndrome compared to placebo |
|
|
| Not yet recruiting | 2 | 30 | Europe | Anifrolumab, Infusion, Saphnelo | University Medical Centre Groningen, AstraZeneca BV | Primary Sjögren's syndrome. Patients will be included if the fulfil the 2016 ACR/EULAR classification criteria for pSS and if they have active disease according to an ESSDAI score of 5 or more and/or an ESSPRI score of 5 or more., Primary Sjögren's syndrome, a systemic, auto-immune disease., Diseases [C] - Immune System Diseases [C20] | | | | |
| Recruiting | 2 | 30 | Europe | Anifrolumab, Saphnelo, Placebo | University Medical Center Groningen, AstraZeneca | Sjogren's Syndrome | 05/24 | 08/24 | | |
| Recruiting | 2 | 15 | US | Anifrolumab, anifrolumab-fnia, Saphnelo | University of North Carolina, Chapel Hill, AstraZeneca | Hidradenitis Suppurativa, Acne Inversa, Hidradenitis | 06/26 | 12/26 | | |
NCT05440422: The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD |
|
|
| Recruiting | 2 | 45 | US | anifrolumab, Placebo | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis | 08/26 | 08/26 | | |
VITANI, NCT05917561: Efficacy and Tolerance of the Association of ANIFROLUMAB (300mg) IV Every Four Weeks and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo |
|
|
| Recruiting | 2 | 48 | Europe | Anifrolumab Infusion Product, Placebo | University Hospital, Bordeaux, AstraZeneca | Vitiligo | 05/26 | 05/26 | | |
